MapLight Therapeutics ($MPLT): Why the Stock Collapsed After a “Positive” Schizophrenia Trial

ZEPHYR met its primary endpoint with the twice-daily dose of ML-007C-MA, yet MapLight lost roughly two-thirds of its value intraday. The apparent contradiction disappears once efficacy magnitude, dosing convenience, competitive benchmarks, expectations and the remaining regulatory path are examined together.





